

NET ASSET VALUE – 31 May 2026

On the 31 May 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,466 million and NAV per share was SEK 36.44. Return on NAV* in the month was -0.34%.

Allocation of NAV	Share of portfolio company	Fair value (MSEK)	Part of NAV per share (SEK)	Share of NAV
Product Development				
Lipum	100%	348	3.66	10.0%
Prokarium	50%	277	2.91	8.0%
Empros Pharma	79%	204	2.15	5.9%
KAHR Medical	34%	199	2.09	5.7%
Xspray Pharma	17%	198	2.08	5.7%
Atrogi	44%	197	2.07	5.7%
Bonsai Biotherapeutics	100%	158	1.66	4.6%
Microbiotica	10%	124	1.31	3.6%
Xintela	60%	110	1.16	3.2%
AnaCardio	13%	79	0.83	2.3%
Mendus	23%	75	0.79	2.2%
Geneos Therapeutics	12%	66	0.70	1.9%
EpiEndo Pharmaceuticals	9%	53	0.56	1.5%
Vitara Biomedical	11%	52	0.55	1.5%
Buzzard Pharmaceuticals	15%	33	0.35	1.0%
Egetis Therapeutics	1%	29	0.30	0.8%
Amarna Therapeutics	58%	11	0.11	0.3%
Strike Pharma	18%	11	0.11	0.3%
Total		2,225	23.40	64.2%
Commercial Growth				
Symcel	30%	204	2.15	5.9%
NorthX Biologics	61%	202	2.12	5.8%
Chromafora	28%	137	1.45	4.0%
Nanologica	50%	104	1.09	3.0%
Frontier Biosolutions	2%	26	0.27	0.7%
Bohus Biotech	45%	0	0.00	0.0%
Total		673	7.08	19.4%
Assets related to Portfolio companies		211	2.22	6.1%
Other assets and liabilities		356	3.74	10.3%
Net Asset Value		3,466	36.44	100.0%

* Following the bonus issue of 11,888,785 shares conducted in May, which will be followed by a cancellation of 8,412,578 shares to be approved in June, the return for the month is calculated on total NAV instead of as previously NAV per share.

For more information:

Ted Fjällman, CEO

Email: ir@flerie.com

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

[NET ASSET VALUE - 31 May 2026](#)